Indian and European companies collaborate to fight cancer
Personalised cancer care is a step closer to realising its potential, with a collaboration announced between Belgian precision oncology firm OncoDNA, and Converge Biotech, a healthcare firm based in Hyderabad, India.
The focus of the long-term alliance is to forge forward with the development of personalised care for late-stage cancer patients, across India and further afield. OncoDNA offerings help medics make the most effective choices for treatments, based on the genetic profile of a patient’s tumour. Effective, selective treatments seek to improve the outcomes for those patients with advanced cancers. The new collaboration will allow Converge Biotech to offer doctors OncoDNA’s range of diagnostic solutions.
“Giving oncologists access to cancer biomarker testing is key to improve the treatment journey of patients living with cancer. To date, OncoDNA’s solutions have helped more than 20,000 patients worldwide. We are delighted to have found in Converge Biotech a trusted partner to support together the adoption of precision medicine for the benefit of cancer patients in India,” said Corina Cucuruzac, Head of Global Distribution of OncoDNA.
The solutions offered by OncoDNA cover a range of biomarker-based analyses of biopsies and tissue samples, screening for specific genetic markers from the tumours to facilitate selection of the most effective treatments.
Arun Kumar Bijjala, Managing Director of Converge Biotech Pvt Ltd., added, “Ever since its inception, Converge has embraced products and technologies that ensure better treatment outcomes in chronic illnesses, and made conscious efforts to make these accessible to clinicians and patients with ease. Specialized diagnostic services in the oncology domain extends our vision of enabling medical community to make informed decisions and ensure better treatment outcomes. With this, we expect to bring in a ray of hope to a large number of cancer-affected patients in India, whose treatment outcomes can be enhanced in light of accurate diagnosis.”